| Code | CSB-RA025833MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Sevacizumab, targeting vascular endothelial growth factor A (VEGFA), a critical signaling protein that regulates angiogenesis and vascular permeability. VEGFA plays a central role in both physiological and pathological blood vessel formation by binding to VEGF receptors on endothelial cells, promoting their proliferation, migration, and survival. Aberrant VEGFA signaling is implicated in various disease conditions, including tumor angiogenesis in multiple cancer types, age-related macular degeneration, diabetic retinopathy, and other neovascular disorders where excessive blood vessel growth contributes to disease progression.
Sevacizumab is a therapeutic monoclonal antibody designed to neutralize VEGFA, thereby inhibiting its pro-angiogenic activity. This biosimilar provides researchers with a valuable tool for investigating VEGFA-mediated pathways, studying angiogenesis mechanisms, evaluating anti-angiogenic strategies, and exploring the role of VEGF signaling in tumor microenvironments and vascular diseases. The antibody serves as an important reagent for preclinical studies examining therapeutic interventions targeting the VEGF pathway.
There are currently no reviews for this product.